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Introduction: IgG4-related disease (IgG4-RD) is a multisystem-involved autoimmune disease. Abnormally activated
and differentiated B cells may play important roles. Regulatory B cells (Breg) are newly defined B cell subgroups
with immunosuppressive functions. In this study, we investigated the differences of B cell subsets, the expressions
of co-stimulatory molecules on B cells, and the function of Breg cells in patients with IgG4-RD, primary Sjögren’s
syndrome (pSS) as well as in healthy controls (HC).
Methods: Newly diagnosed IgG4-RD patients (n = 48) were enrolled, 38 untreated pSS patients and 30 healthy
volunteers were recruited as disease and healthy controls. To analyze B cell subsets and B cell activity, PBMCs were
surface stained and detected by flow cytometry. The function of Breg cells was tested by coculturing isolated
CD19 + CD24hiCD38hi Breg cells with purified CD4 + CD25- T cells. Serum cytokines were measured by ELISA and
cytometric bead array. Relationship between clinical data and laboratory findings were analyzed as well.
Results: Compared with pSS patients and HC, IgG4-RD patients had a lower frequency of peripheral Breg cells.
Interestingly, CD19 + CD24-CD38hi B cell subsets were significantly higher in peripheral B cells from IgG4-RD
patients than in pSS patients and HC, which correlated with serum IgG4 levels. The expression of BAFF-R and CD40
on B cells was significantly lower in IgG4-RD patients compared with those in pSS patients and HC. Unlike HC, Breg
cells from pSS patients lacked suppressive functions.
Conclusions: B cells in patients with IgG4-RD and pSS display a variety of abnormalities, including disturbed B cell
subpopulations, abnormal expression of key signaling molecules, co-stimulatory molecules, and inflammatory
cytokines. In addition, a significantly increased B cell subset, CD19 + CD24-CD38hi B cells, may play an important
role in the pathogenesis of IgG4-RD.Introduction
In recent years, a large amount of studies emphasized
the status of B cells in the development of autoimmune
diseases. It is well established that B cells play an in-
flammatory role through effective antigen presentation,
production of auto-antibodies, and secretion of pro-in-
flammatory factors. However, B cells also produce a* Correspondence: zhangwen91@sina.com
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unless otherwise stated.source of inhibitory cytokines, such as IL-10 and tumor
growth factor (TGF)-β. Regulatory B cells (Breg), a group
of new B cell members with the ability to inhibit the im-
mune response, play an important role in maintaining the
balance and tolerance in immune function [1-4].
IgG4-related disease (IgG4-RD) is a newly recognized
systemic inflammatory condition characterized by tume-
factive lesions, elevated serum IgG4 levels (>135 mg/dl),
and IgG4+ plasma cell infiltration (IgG4+ cells in tissue
account for more than 40% of the total number of
plasma cells) [5]. The disease can affect multiple organs. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gland, pancreas, retroperitoneal tissue, and the bile duct,
resulting in swelling and sclerosis of the involved organs.
The complications of IgG4-RD include Mikulicz’s disease
(MD), autoimmune pancreatitis, retroperitoneal fibrosis,
tubulointerstitial nephritis, and Riedel’s thyroiditis, et al.
Previous studies have found that Th2 cells are predo-
minantly activated at affected sites. Collected peripheral
blood mononuclear cells (PBMCs) from IgG4-RD pa-
tients principally produce Th2-type cytokines, which in-
dicates that a Th1-Th2 imbalance may play a crucial
role in IgG4-RD [6,7]. However, the role of B cells in the
pathogenesis of IgG4-RD remains unclear.
Primary Sjögren’s syndrome (pSS) is a systemic auto-
immune disease affecting the exocrine glands, primarily
the lacrimal and salivary glands, resulting in dryness of
the eyes and mouth [8]. There are several similarities
between IgG4-RD and pSS. First, both diseases present
with hypergammaglobulinemia. Next, in both diseases,
the characteristic features of involved tissues are massive
lymphocyte infiltration or even generation of germinal
centers. Furthermore, both diseases are systemic with
multiple organ involvement, especially lacrimal and sali-
vary glands. MD, a singular IgG4-RD, was considered
part of pSS for a long time [9]. Finally, both diseases re-
spond well to corticosteroid therapy.
To date, the role of Breg cells has been identified in the
regulation of several immune-mediated processes of dif-
ferent disease types, such as autoimmune diseases [10-12],
infectious disease [13], and cancer [14]. It has been de-
monstrated that human peripheral CD19 + CD24hiCD38hi
Breg cells possess regulatory function in immune respon-
ses. Given abnormal B cells are generally considered as
one of key mechanisms of pSS, we hypothesize that B cell
abnormality participates in the pathogenesis of IgG4-RD.
In this study, we evaluated the peripheral B cell subsets,
especially Breg cells in IgG4-RD patients, pSS patients,
and HC, as well as B cell co-stimulatory and activation
markers of CD80, CD86, CD40, and B cell activating factor
receptor expression. The correlations of B cell subsets with
clinical features were analyzed as well. The immune regu-
latory function of Breg cells was explored in order to ex-
plain the role(s) of Breg in the pathogenesis of IgG4-RD.
Materials and methods
Patients and controls
Untreated patients with IgG4-RD (n = 48), untreated pa-
tients with pSS (n = 38), and healthy controls (HC) (n = 30)
were enrolled in this study. Patients with IgG4-RD and pSS
fulfilled the 2011 comprehensive IgG4-RD diagnostic cri-
teria [15], and the 2002 European/American consensus
group diagnostic criteria [16], respectively. The diagnosis
of IgG4-RD was based on the following three items:
1) clinical examination showing characteristic diffuse/localized swelling or masses in single or multiple organs; 2)
hematological examination showing elevated serum IgG4
concentration (>135 mg/dl); 3) histopathologic examin-
ation showing: (A) marked lymphocytes and plasma cells
infiltration and fibrosis, or (B) infiltration of IgG4+ plasma
cells (ratio of IgG4+/IgG + cells >40% and >10 IgG4+
plasma cells/high power field). Patients with cancer or
lymphoma and other autoimmune diseases were excluded.
In this study, only those untreated pSS patients with hyper-
gammaglobulinemia were included. Age-matched healthy
individuals were studied in parallel as controls. The study
was approved by the Medical Ethics Committee of Peking
Union Medical College Hospital (Peking, China). Written
informed consent was obtained from all patients and HC.
Phenotypic analysis of peripheral B cells by flow
cytometry
Peripheral blood mononuclear cells (PBMCs) from IgG4-
RD, pSS, and HC were prepared according to standard
Ficoll-Hypaque procedures (Pharmacia Biotech, Uppsala,
Sweden), and were stained with PE-CY7-anti-CD19, FITC-
anti-CD24, APC-anti-CD38, PE-anti-CD40, PE-anti-CD80,
PE-anti-CD86, PE-anti-BAFF-R, PE-anti-TACI mAb (BD
Biosciences, San Jose, CA, USA), and PE-anti-BCMA mAb
(Biolegend, San Diego, CA, USA) or isotype-matched
controls. After incubation for 30 minutes at 4°C, the cells
were washed and resuspended in fluorescence-activated
cell sorter (FACS) staining buffer (BD Biosciences). All ex-
periments were analyzed by gating on lymphocytes accor-
ding to forward side scatter/side light scatter; dead or
dying cells or granulocytes were excluded. B-cell subsets
were gated on CD19, and then gated on CD24 and CD38
[17]. Flow cytometry analysis was performed immediately
after sample preparation. All samples were analyzed using
a FACS AriaII (BD Biosciences)and data were analyzed by
FlowJo v.7.6.4 Software (Tree Star, Stanford University,
CA, USA).
Cell isolation and culture
Cell isolation
PBMCs were stained with CD19, CD24, and CD38 anti-
bodies, and then CD19 + CD24 + CD38-memory B cells
and CD19 + CD24hiCD38hi Breg cells were sorted with a
MoFlo high-performance cell sorter (Cytomation, Fort
Collins, CO, USA). CD4 + CD25- effector T cells were
purified by magnetic-bead separation with MACS kits
(Miltenyi, Gladbach, Germany) according to the manu-
facturer’s instructions, achieving >95% purity.
Cell culture
To test the function of Breg cells, co-cultured cells (Breg
cells and CD4 + CD25- T cells from patients or healthy
donors at a ratio of 1:1, 5*104 cells/well) were resus-
pended in Roswell Park Memorial Institute (RPMI) 1640
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cillin 100 IU/mL, streptomycin 100 μg/mL; Invitrogen,
Camarillo, CA, USA) in 96-well U-bottom plates (Nunc,
Langenselbold, Germany) in a humidified atmosphere of
5% CO2 at 37°C, in the presence of 0.5 μg/mL purified
plate-bound CD3 monoclonal antibody, 100 ng/mL
recombinant human CD40L (Abcam, Cambridge, MA,
USA), 0.1 μg/mL cytosine-phosphate-guanosine oligo-
deoxynucleotide 2006 (CpG ODN 2006, Invivogen, San
Diego, CA, USA). From the same healthy donor, 100,000
PBMCs depleted of CD4+ T cells by magnetic-bead puri-
fication, were incubated with 25 μg/mL mitomycin C at
37°C for 30 minutes, and were added to co-cultures as
feeder cells.
For the experiment with memory B cells, purified
CD19 + CD24 + CD38- memory B cells from IgG4-RD,
pSS patients and HC were resuspended in RPMI1640
medium supplemented with 10% FCS and antibiotics in
96-well U-bottom plates in a humidified atmosphere of
5% CO2 at 37°C with 1 × 105 in each well. For each
group, 100 ng/mL recombinant human CD40L (Abcam)
and 0.1 μg/mL CpG ODN 2006 (Invivogen) was added
at the beginning.
To test the effect of BAFF-induced BAFF-R expres-
sion, PBMCs were cultured with or without rhBAFF
(R&D Systems, Minneapolis, MN, USA), at the concen-
tration similar to the range observed in the serum of pa-
tients with IgG4-RD. Cells were cultured for 48 h, then
BAFF-R expression on B cells was analyzed by FACS
gating on live lymphocytes.
Intracellular cytokine analysis
For intracellular cytokine measurement, cells were incu-
bated with PMA (20 ng/mL, Sigma-Aldrich, St Louis,
MO, USA), ionomycin (1,000 ng/mL, Sigma-Aldrich)
and GolgiPlug (1ul/mL, BD Biosciences) for the last 5 h.
After surface staining with CD4-PerCP-CY5.5, cells were
washed, fixed, permeabilized, and stained with interferon
(IFN)-γ-APC and TNF-α-APC mAbs (BD Biosciences).
Appropriate APC-conjugated isotype controls were used
for gate setting of cytokine expression.
Enzyme-linked immunosorbent assay (ELISA) and
cytometric bead array (CBA) analysis
Serum samples from enrolled patients and controls were
collected and were stored at -80°C until used. Serum
cytokine levels of IgG4-RD, pSS, and HC were measured
by human ELISA kits (R&D Systems) according to the
manufacturer’s instructions. CBA analysis for IgG4 in
supernatants was performed according to the manufac-
turer’s instructions (BD Biosciences). Data were analyzed
using CBA analysis software from BD Biosciences. The
concentration of IgG4 in supernatants was determined
by reference to a standard curve.Clinical data and inflammatory parameters
Clinical data including age, gender, disease duration, and
manifestations were reported in all patients. Laboratory
findings were recorded, including erythrocyte sedimen-
tation rate (ESR), C-reactive protein (CRP), serum im-
munoglobulin (Ig)G, IgA, IgM, and IgG subsets.
Statistical analysis
Results were summarized as mean ± SD and standard error
of the mean (SEM). Quantitative comparisons involved the
Mann-Whitney U test for unpaired data and the Wilcoxon
test for paired data. The relationship between frequency
levels of B-cell subsets and clinical features in IgG4-RD
and pSS patients were analyzed by Pearson’s rank test. All
statistical analyses were performed using SPSS v.17.0 statis-
tics package software (IBM, USA) and GraphPad Prism
software version 5.0 (Graph-Pad, San Diego, CA, USA). A
P-value <0.05 was considered significantly different.
Results
Patient characteristics
Demographic, clinical, and laboratory characteristics of en-
rolled IgG4-RD patients, pSS patients, and HC are summa-
rized in Table 1. There was no statistical difference in total
serum IgG levels between IgG4-RD (24.58 ± 10.74 g/L) and
pSS patients (22.99 ± 11.48 g/L; P >0.05); however, the
serum IgA and IgM levels in IgG4-RD patients (1.85 ±
0.76 g/L, 0.82 ± 0.38 g/L, respectively) were significantly
lower compared with those in pSS patients (4.17 ± 2.23 g/L;
P <0.001 and 1.24 ± 0.64 g/L; P = 0.001). Serum IgG4 levels
were remarkably elevated in IgG4-RD patients (1929.10 ±
1923.63 mg/dL), significantly higher than in pSS patients
(36.45 ± 37.74 mg/dL; P <0.001). Furthermore, the ratio of
IgG4/ IgG was significantly increased in IgG4-RD patients.
Decreased regulatory and mature but increased memory
B cells in IgG4-RD patients
In order to evaluate possible changes in B-cell populations
in IgG4-RD and pSS patients, we compared the percen-
tages of total, regulatory, mature, and memory B cells in
peripheral blood. According to previous reports [11,17-19],
B cell subsets were briefly defined as mature (CD19 +
CD24intCD38int), memory (CD19 +CD24 +CD38-) and
regulatory (CD19 + CD24hiCD38hi) B cells (Figure 1A).
The percentages of CD19+ B cells were significantly in-
creased in IgG4-RD patients (6.43 ± 2.73%) compared to
HC (4.41 ± 1.75%; P = 0.001), but were lower than in pSS
patients (8.97 ± 4.40%; P <0.001; Figure 1B). The median
fluorescence intensity (MFI) of CD19+ B cells was signifi-
cantly different among three groups (HC: 145.50 ± 27.62;
IgG4-RD: 207.9 ± 65.50; pSS: 259.80 ± 90.79; P <0.001).
The frequency of regulatory B cells in IgG4-RD patients
was lower compared with pSS patients and HC (2.17 ±
3.96%, 12.55 ± 5.15%, and 3.98 ± 2.70%, respectively;
Table 1 Clinical and laboratory findings in IgG4-related disease, primary Sjögren’s syndrome and healthy controls
Healthy controls IgG4-related disease Primary Sjögren’s syndrome
Number 30 48 38
Gender, male/female, n 7/23 29/19 3/35
Age, years 46.4 ± 10.0 53.17 ± 13.66*** 42.2 ± 9.6
Disease duration, months NA 29.45 ± 41.35* 51.32 ± 47.6
ESR, mm/h NA 49.35 ± 33.80** 30.68 ± 28.35
C-reactive protein, mg/L NA 9.17 ± 3.67** 2.65 ± 1.64
Immunoglobulin (Ig)G, g/L 10.11 ± 1.47 24.58 ± 10.74 22.99 ± 11.48
IgA, g/L 2.28 ± 0.74 1.85 ± 0.76*** 4.17 ± 2.23
IgM, g/L 1.02 ± 0.50 0.82 ± 0.38** 1.24 ± 0.64
IgG1, mg/dL 797.83 ± 106.54 1036.55 ± 670.09** 1485.74 ± 486.36
IgG2, mg/dL 554.6 ± 228.80 592.76 ± 396.55** 372.95 ± 126.70
IgG3, mg/dL 41.68 ± 22.10 78.61 ± 64.05 60.03 ± 41.41
IgG4, mg/dL 57.06 ± 46.06 1929.10 ± 1923.63*** 36.45 ± 37.74
IgG4/total IgG%1 3.90 ± 3.10 39.03 ± 25.84*** 1.86 ± 1.85
Values are shown as mean ± SD unless stated otherwise. 1IgG level is the sum of IgG1, IgG2, IgG3 and IgG4. ***P <0.001; **P <0.01; *P <0.05 (compared with
Primary Sjögren’s syndrome). ESR, erythrocyte sedimentation rate; NA, not applicable.
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centages of mature B cells in IgG4-RD patients compared
with pSS patients and HC (36.68 ± 14.27%, 49.75 ± 11.59%,
and 53.70 ± 15.12%, respectively; P <0.001; Figure 1D). In
contrast, IgG4-RD patients had increased percentages of
memory B cells compared with HC and pSS patients
(22.71 ± 12.81%, 14.01 ± 10.39%, and 15.79 ± 10.58%, re-
spectively; P <0.01; Figure 1E). Figure 1F summarizes
the percentages of B-cell subsets in the IgG4-RD, pSS,
and HC.
Interestingly, an undefined CD19 + CD24-CD38hi B-cell
population was significantly increased in IgG4-RD patients
(6.99 ± 6.24%) compared with those from pSS (2.39 ±
2.64%; P <0.001) and HC (2.16 ± 1.65%; P <0.001;
Figure 1G). Table 2 summarizes the proportions of B-cell
subsets in IgG4-RD, pSS and HC.
In addition, after one to three months of glucocorticoids
treatment, the ratio of CD19 + CD24-CD38hi B cells de-
creased to 2.54 ± 2.28% in IgG4-RD patients (P = 0.01),
whereas there were no statistically significant changes in
other B-cell subgroups.
Decreased expression of BAFF-R on peripheral B-cell
subsets in IgG4-RD patients
BAFF-R expression was tested in 38 IgG4-RD patients,
20 pSS patients and 20 HC. The frequency of BAFF-R
expression on B cells was significantly lower in IgG4-RD
patients compared with HC (76.63 ± 20.85% and 94.13 ±
3.50%; P <0.01), but was comparable to pSS patients
(88.96 ± 8.90%; P = 0.066; Figure 2A, B). Moreover, MFI of
BAFF-R in CD19+ B cells from IgG4-RD patients was
lower than in HC (243.9 ± 149.35 and 430.56 ± 109.28,respectively; P <0.001), but was similar to that in pSS pa-
tients (323.5 ± 96.46; P >0.05).
As B-cell subpopulation homeostasis was disturbed in
IgG4-RD and pSS, we analyzed BAFF-R expression in dif-
ferent B-cell subsets. The percentages of BAFF-R + Breg
cells were significantly lower in IgG4-RD patients com-
pared with HC (69.47 ± 35.31%, 94.66 ± 11.23%, respec-
tively; P = 0.01), while there was no significant difference
compared with pSS patients (93.58 ± 10.69%; P = 0.15;
Figure 2C). The MFI of BAFF-R in Breg cells of IgG4-RD
patients was lower than that of HC (208.5 ± 218.4, 344.1 ±
158.4, respectively; P <0.05) and pSS patients (340.4 ±
114.5; P <0.05). The proportions of BAFF-R +mature
B cells were significantly decreased in IgG4-RD patients
compared with pSS patients and HC (72.27 ± 28.91%,
92.59 ± 92.7%, and 97.78 ± 1.51%, respectively; P <0.05;
Figure 2D). Meanwhile, the MFI of BAFF-R on mature B
cells of IgG4-RD patients (193.1 ± 180.9) was lower than
that of pSS patients (374.0 ± 136.5; P = 0.02) and HC
(465.5 ± 109.2; P <0.001), whereas there was no significant
difference between pSS patients and HC. Regarding the
percentages of BAFF-R expression on memory B cells,
there was no difference among IgG4-RD, pSS, and HC
(IgG4-RD: 82.78 ± 21.63%; pSS: 86.06 ± 10.35%; HC:
90.21 ± 10.08%; P = 0.30; Figure 2E). Similarly, the MFI
of BAFF-R on memory B cells was not statistically dif-
ferent in the three groups (IgG4-RD: 280.1 ± 124.2; pSS:
286.8 ± 101.0; HC: 364.2 ± 140.7; P = 0.10).
The percentages of BAFF-R + CD19 + CD24-CD38hi
B cells were significantly decreased in IgG4-RD compared
with pSS patients (23.29 ± 20.83%, 34.91 ± 19.65%, respec-
tively; P = 0.045), and were comparable to HC (32.31 ±
Figure 1 Expression of B-cell subsets in IgG4-related disease (RD), primary Sjögren’s syndrome (pSS), and healthy controls (HC).
Representative flow cytometry pictures of different B-cell subsets from HC, IgG4-RD, and pSS patients (A). The percentages of CD19+ B cells out
of total lymphocytes in each group (B). Percentages of Breg cells, mature B cells, and memory B cells out of total B cells in each group (C, D, E).
Summary of different B-cell subsets in different populations (F). Percentages of CD19 + CD24-CD38hi B cells out of total B cells in each group (G).
Values are shown as mean ± standard error of the mean, *P <0.05, **P <0.01, ***P <0.001.
Table 2 B cell phenotypes in IgG4-RD, pSS and healthy controls
Healthy
controls
IgG4-RD pSS IgG4-related disease versus HC pSS versus HC IgG4-RD versus pSS
P-value P-value P-value
CD19+ (%)1 4.41 ± 1.75 6.43 ± 2.73 8.97 ± 4.40 0.001 <0.001 0.009
CD19 + CD24 + CD38- (%)2 14.01 ± 10.39 22.71 ± 12.81 15.79 ± 10.58 0.002 0.541 0.009
CD19 + CD24intCD38int (%)2 53.70 ± 15.12 36.68 ± 14.27 49.75 ± 11.59 <0.001 0.150 <0.001
CD19 + CD24hiCD38hi (%)2 3.98 ± 2.70 2.17 ± 3.96 12.55 ± 5.15 <0.001 <0.001 <0.001
CD19 + CD24-CD38hi (%)2 2.16 ± 1.65 6.99 ± 6.24 2.39 ± 2.64 <0.001 0.868 <0.001
CD19 + CD40+ (%)2 87.08 ± 11.27 44.35 ± 21.79 69.48 ± 20.33 <0.001 <0.001 <0.001
CD19 + BAFF-R + (%)2 94.13 ± 3.50 76.63 ± 20.85 88.96 ± 8.90 0.001 0.005 0.066
CD19 + CD80+ (%)2 17.54 ± 7.41 43.27 ± 8.64 23.69 ± 14.24 <0.001 0.327 0.037
CD19 + CD86+ (%)2 19.56 ± 7.70 47.18 ± 14.23 27.45 ± 12.17 0.002 0.325 0.041
Values are shown as mean ± SD. 1Percentages of CD19+ cells in total lymphocytes. 2Percentages of B cell subsets in CD19+ cells. IgG4-RD, IgG4-related disease;
pSS, primary Sjögren’s syndrome.
Lin et al. Arthritis Research & Therapy 2014, 16:R118 Page 5 of 14
http://arthritis-research.com/content/16/3/R118
Figure 2 (See legend on next page.)
Lin et al. Arthritis Research & Therapy 2014, 16:R118 Page 6 of 14
http://arthritis-research.com/content/16/3/R118
(See figure on previous page.)
Figure 2 Expression of BAFF-R, CD40, CD80, and CD86 on peripheral B cells in IgG4-related disease (RD), primary Sjögren’s syndrome
(pSS), and healthy controls (HC). Representative flow cytometry pictures of BAFF-R expression on CD19+ B cells of HC, IgG4-RD, and pSS patients
(A). Scatter plots showing the percentages of CD19 + BAFF-R + cells in CD19+ cells (B). Scatter plots of the percentages of BAFF-R + expression on
different B cell subsets (C-F). The changes in mean fluorescence intensity (MFI) of BAFF-R from healthy subjects after stimulation with recombinant
human BAFF (rhBAFF) for 48 h (G). One representative example of decreased BAFF-R MFI on B cells by flow cytometry after 48 h culture in the
presence of rhBAFF (2 ng/mL) (H). Representative flow cytometry of CD40 expression on CD19+ B cells of HC, IgG4-RD, and pSS patients (I). Scatter
plots showing the percentages of CD19 + CD40+ cells in CD19+ cells (J-K). Percentages of CD80 and CD86 expression on CD19+ B cells of HC,
IgG4-RD, and pSS patients (L,M). Values are shown as mean ± standard error of the mean, *P <0.05; **P <0.01; ***P <0.001.
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the MFI of BAFF-R on CD19 + CD24-CD38hi B cells
were found among three groups (IgG4-RD: 11.37 ± 13.62;
pSS: 13.39 ± 9.79; HC: 11.43 ± 5.32).
In the meantime, the expression of other two kinds of
BAFF receptors, B-cell maturation antigen (BCMA) and
transmembrane activator and calcium modulator (TACI)
were tested, which showed no significant difference
among IgG4-RD, pSS and HC. The frequency of BCMA
expression on B cells was comparable in IgG4-RD pa-
tients and pSS patients and HC (5.19 ± 1.48%, 5.80 ±
3.29%, and 5.42 ± 1.78%, P = 0.97; respectively). Similarly,
the frequency of TACI on B cells was not statistically
different among the three groups (IgG4-RD: 5.56 ±
1.63%; pSS: 5.33 ± 1.59%; HC: 4.69 ± 0.51%; P = 0.82).
To determine the response of BAFF-R to BAFF stimula-
tion, PBMC from healthy subjects were incubated with or
without rhBAFF at a concentration similar to the range
observed in the serum of patients with IgG4-RD for 48 h.
The MFI of BAFF-R decreased with stimulation of
rhBAFF (from 554.80 ± 230.2 to 166.8 ± 92.66; P <0.01;
Figure 2G-H), indicating that expression of BAFF-R might
be inhibited by chronic BAFF overproduction in IgG4-RD
patients.
Decreased expression of CD40 but increased expression
of CD80 and CD86 on peripheral B cell subsets in
IgG4-RD patients
CD40, CD80 and CD86 expressions were tested in 38
IgG4-RD patients, 20 pSS patients and 20 HC. Both the
percentage and the MFI of CD40 on CD19+ B lympho-
cytes were lower in IgG4-RD patients (44.35 ± 21.79%,
12.32 ± 6.28, respectively) compared with those in pSS pa-
tients (69.48 ± 20.33%; P <0.001 and 21.47 ± 8.23; P <0.001;
respectively) and in HC (87.08 ± 11.27%; P < 0.001 and
27.32 ± 6.13; P <0.001; respectively; Figure 2I-J). Analysis
of MFI revealed that CD40 expression on both regulatory
and mature B cells was lower in IgG4-RD patients
(14.28 ± 8.91, 12.70 ± 7.14, respectively) compared with
those in pSS patients (24.13 ± 6.06; P <0.001 and 26.09 ±
6.90; P <0.001; respectively) and in HC (20.75 ± 5.72;
P <0.05 and 23.93 ± 5.86; P <0.001; respectively). The MFI
of CD40 on memory B cells was significantly lower inIgG4-RD than in pSS patients (16.48 ± 6.68, 25.55 ± 13.63,
respectively; P <0.05).
Next we evaluated the expression of co-stimulatory
molecules of B cells, CD80 and CD86. The results re-
vealed that CD19+ B lymphocytes in IgG4-RD patients
expressed significantly higher CD80 and CD86 (43.27 ±
8.64%, 47.18 ± 14.23%, respectively) than in pSS patients
(23.69 ± 14.24%; P = 0.037 and 27.45 ± 12.17%; P = 0.041;
respectively) and HC (17.54 ± 7.41%; P <0.001 and 19.56 ±
7.70%; P = 0.002, respectively; Figure 2K-M).
Breg cells are deficient in inhibition of proinflammatory
cytokine production by T cells in pSS patients
To assess the function of regulatory B cells in pSS patients,
magnetic-bead-purified CD4 +CD25-effector T cells (Teff)
were cultured alone or 1:1 with flow-cytometry sorted
CD19 +CD24hiCD38hi cells, stimulated for 72 h with
0.5 μg/mL plate-bound CD3 mAb, 100 ng/mL CD40L and
0.1 μg/mL CpG ODN 2006. GolgiPlug was added during
the final 5 h along with PMA (20 ng/mL) and ionomycin
(1000 ng/mL). Cells were surface-stained for the expression
of CD4 and intracellular stained for IFN-γ and TNF-α. The
expression of IFN-γ and TNF-α was evaluated by flow
cytometry. Isotype-matched mAbs were set as negative
controls (Figure 3A, H). The results revealed that, in
HC, co-culture of CD4 +CD25- T cells with CD19 +
CD24hiCD38hi B cells suppressed the frequencies of CD4 +
IFN-γ + (Figure 3C) and CD4 +TNF-α + (Figure 3J) cells
compared with effector T cells alone (Figure 3B, I). In con-
trast, compared with effector T cells alone (Figure 3E, L),
CD19 +CD24hiCD38hi Breg cells from pSS patients did not
show effects of suppressing proinflammatory cytokines by
CD4 +CD25- effector T cells (Figure 3F, M).
Next, we evaluated whether Teff cells from pSS pa-
tients were resistant to the suppressive effect of Breg
cells or whether there was malfunction of Breg cells.
Heterologous Teff/Breg cells from HC and Breg/Teff
cells from pSS patients were cross-cultured at 1:1 in the
same condition. The results demonstrated that IFN-γ
and TNF-α expressed by pSS Teff cells could be sup-
pressed by healthy Breg cells, indicating that the sup-
pressive function of Breg cells from pSS patients was
deficient (Figure 3D, G, K, N).
Figure 3 Inhibiting function of Breg cells in primary Sjögren’s syndrome (pSS) patients. Magnetic-bead purified CD4 + CD25- effector T cells
were cultured alone or 1:1 with flow-cytometry sorted CD19 + CD24hiCD38hi cells, stimulated for 72 h with 0.5 μg/mL plate-bound CD3 monocolonal
antibodies (mAb), 100 ng/mL CD40L and 0.1 μg/mL CpG ODN 2006. GolgiPlug was added during the final 5 h along with PMA + Iono. Cells were
surface-stained for the expression of CD4 and intracellular-stained IFN-γ and TNF-α. Expression of IFN-γ and TNF-α were assessed by flow cytometry.
Isotype-matched mAbs were set to be negative controls (A, H). Flow cytometry plots of IFN-γ and TNF-α expression by effector T cells (Teff) alone
(B, E, I, L) or in the presences of CD19 + CD24hiCD38hi B cells are shown (C, F, J, M). Heterologous Teff/Breg cells from HC and Breg/Teff cells from
pSS patients were cross-cultured at 1:1 in the same condition. The results are shown in D, G, K, N. Data are representative of six independent
experiments (six different donors in each group).
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IgG4-RD was not tested because of low frequency. In
addition, isolated B cells from IgG4-RD patients were
stimulated with CD40L and CpG ODN 2006 for 3, 6,
and 9 days, but no induced increase of Breg cells (data
not shown).
CD19 + CD24 + CD38- memory B cells from IgG4-RD
patients secreted more IgG4
CD19 + CD24 + CD38- memory B cells from IgG4-RD,
pSS patients and HC were isolated and cultured in vitro,with CD40L and CpG ODN 2006. At day 7, the culture
supernatants were collected and IgG4 level was eva-
luated by CBA. The results showed that memory B cells
from IgG4-RD patients secreted more IgG4 (IgG4-RD:
161.00 ± 55.91 ng/mL; HC: 6.19 ± 2.40 ng/mL; pSS: 5.86 ±
3.15 ng/mL, respectively; Figure 4).
Serum cytokine levels and BAFF levels in IgG4-RD, pSS,
and HC
IgG4-RD patients (n = 28), pSS patients (n = 28), and
HC (n = 24) were tested for serum cytokine profile.
Figure 4 IgG4 secreting by CD19 + CD24 + CD38- memory B cells from IgG4-related disease patients. Isolated CD19 + CD24 +
CD38- memory B cells from IgG4-RD, primary Sjögren’s syndrome (pSS) patients and healthy controls (HC) were cultured in vitro, stimulated with
CD40L and CpG ODN 2006. At day 7, the supernatants were collected and IgG4 level was evaluated by CBA. The results are shown in A-C.
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5.67 pg/mL) were significantly higher than those in
HC (1.69 ± 1.46 pg/mL; P <0.001), and there were no sig-
nificant differences between IgG4-RD and pSS patients
(6.52 ± 6.14 pg/mL) (Figure 5A), Serum levels of IL-6 in
patients with IgG4-RD (2.14 ± 1.66 pg/mL) were signi-
ficantly higher than those in HC and pSS patients (0.68 ±
0.39 pg/mL, P <0.001; 1.35 ± 1.40 pg/mL; P = 0.002;Figure 5 Serum levels of cytokines and BAFF in IgG4-related disease
(HC). Serum cytokines of IL-4 (A), IL-6 (B), IL-5 (C), IL-13 (D), IL-10 (E), IFN-γ
IgG4-RD (n = 28), pSS patients (n = 28), and HC (n = 24) were tested by ELIS
**P <0.01; ***P <0.001.Figure 5B). Serum levels of IL-13 in patients with IgG4-
RD (3.99 ± 6.15 pg/mL) were comparable to those in HC
(3.18 ± 2.61 pg/mL; P = 0.524), and both were significantly
lower than in patients with pSS (10.05 ± 13.99 pg/mL;
Figure 5D). Serum levels of IL-10 in patients with IgG4-RD
(10.67 ± 5.50 pg/mL) were significantly higher than those
in HC (3.22 ± 1.40 pg/mL; P <0.001), and there were no
significant differences between IgG4-RD and pSS patients(RD), primary Sjögren’s syndrome (pSS), and healthy controls
(F), IL-17A (H), TGF-β (I) and BAFF (G) levels from serum samples of
A. Values are shown as mean ± standard error of the mean, *P <0.05;
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patients with IgG4-RD (2.23 ± 1.56 pg/mL) were com-
parable to those in pSS patients (3.20 ± 3.15 pg/mL;
P = 0.493), and both were significantly higher than in HC
(1.02 ± 0.81 pg/mL; Figure 5F). As shown in Figure 5G,
serum levels of BAFF in patients with IgG4-RD (2.60 ±
2.80 ng/mL) were significantly higher than those in HC
(0.70 ± 0.42 ng/mL; P <0.001), while there were no signifi-
cant differences in serum levels of BAFF between IgG4-RD
and pSS patients (2.31 ± 2.65 ng/mL). Serum levels of
IL-17A in patients with IgG4-RD (0.40 ± 0.57 pg/mL) were
comparable to those in HC (0.24 ± 0.15 pg/mL; P = 0.482),
and both were significantly lower than in patients with pSS
(1.10 ± 1.37 pg/mL; Figure 5H). Serum levels of TGF-β in
patients with IgG4-RD (16.94 ± 7.73 ng/mL) were compar-
able to those in HC (17.73 ± 4.81 ng/mL; P = 0.643), and
both were significantly higher than in patients with pSS
(14.16 ± 5.66 ng/mL; Figure 5I). In addition, there were no
significant differences in the level of IL-5 in patients with
IgG4-RD, pSS or HC (Figure 5C). Table 3 summarized
cytokines expression in IgG4-RD, pSS patients and HC.
Correlation of different B-cell subsets with laboratory
findings in IgG4-RD and pSS patients
The correlation of Breg cells with laboratory findings were
evaluated in IgG4-RD and pSS patients. In IgG4-RD pa-
tients, there was no statistical correlation between the per-
centage of Breg cells and erythrocyte sedimentation rate
(ESR), IgG, IgG4 levels, or IgG4/IgG ratio (Figure 6A-C).
However, the frequencies of memory B-cell subsets were
negatively correlated with serum IgG4, IgG levels and
IgG4/IgG ratio in IgG4-RD patients (r = -0.5127, P = 0.004;
r = -0.4759, P = 0.009; r = -0.4777, P = 0.014, respectively).
Whereas there was no correlation between mature B cells,
ESR, CRP, and serum immunoglobulin levels. As CD19 +
CD24-CD38hi B cells were significantly increased in
IgG4-RD patients, we analyzed the correlation between
percentages of CD19 + CD24-CD38hi B cells and clinicalTable 3 Serum cytokine levels in IgG4-RD, pSS patients and H
HC IgG4-RD pSS
(n = 24) (n = 28) (n = 28)
IL-4, pg/mL 1.69 ± 1.46 6.54 ± 5.67 6.52 ± 6.14
IL-5, pg/mL 1.34 ± 1.03 1.48 ± 1.51 2.23 ± 3.16
IL-6, pg/mL 0.68 ± 0.39 2.14 ± 1.66 1.35 ± 1.40
IL-10, pg/mL 3.22 ± 1.40 10.67 ± 5.50 11.59 ± 7.90
IL-13, pg/mL 3.18 ± 2.61 3.99 ± 6.15 10.05 ± 13.99
IL-17A, pg/mL 0.24 ± 0.15 0.40 ± 0.57 1.10 ± 1.37
IFN-γ, pg/mL 1.02 ± 0.81 2.23 ± 1.56 3.20 ± 3.15
TGF-β, ng/mL 17.73 ± 4.81 16.94 ± 7.73 14.16 ± 5.66
BAFF, ng/mL 0.70 ± 0.42 2.60 ± 2.80 2.31 ± 2.65
Values are shown as mean ± SD. IgG4-RD, IgG4-related disease; pSS, primary Sjögrenfindings. The frequencies of CD19 + CD24-CD38hi B cells
were positively correlated with IgG4 levels and the IgG4/
IgG ratio in IgG4-RD patients (r = 0.4875, P = 0.0063;
r = 0.3987, P = 0.0321; respectively; Figure 6G-H), indi-
cating that CD19 + CD24-CD38hi B cells might play an im-
portant role in IgG4-RD.
In contrast to IgG4-RD patients, we found that the
frequency of Breg cells were correlated with ESR and
serum IgG levels in pSS patients (r = 0.5292, P = 0.0032;
r = 0.4376, P = 0.0109, respectively). However, there was
no correlation between Breg frequencies and serum IgA
and IgM levels. When observing other B-cell subsets, we
found that the frequency of mature B cells was negatively
correlated with ESR and serum IgG levels in pSS patients
(r = -0.5042; P = 0.0038 and r = -0.3725; P = 0.0328, re-
spectively). However, there was no correlation between
memory B-cell frequencies, ESR, and serum immuno-
globulin levels.
Discussion
Regulatory B cells, as emerging immunoregulatory B-cell
subsets, are considered an important regulator of the im-
mune system [3,20,21]. Regulatory B cells are shown to
play a vital role in various immune responses and diseases,
including contact hypersensitivity and systemic autoim-
mune diseases. In this study, we tested the percentages of
CD19+ B cells and its subsets, including regulatory,
mature, and memory B cells in peripheral blood from
IgG4-RD and pSS patients. According to Carsetti et al.
and Blair et al., human Breg cells are a subset of B cells
that express CD19 + CD24hiCD38hi [11,17]. Our data
revealed that in contrast to HC, IgG4-RD patients had a
significantly lower frequency of Breg cells, whereas pSS
patients had a significantly higher frequency, although
both diseases are characterized by hypergammaglobuline-
mia. We further tested the potential immune regulatory
functions of Breg cells from pSS patients, which showed
that unlike Breg cells from HC, CD19 + CD24hiCD38hiC











’s syndrome; HC, healthy controls.
Figure 6 Correlation of different B-cell subsets with laboratory findings in IgG4-related disease (RD) patients. Correlations between the
percentages of CD19 + CD24hiCD38hi Breg cells and levels of IgG, IgM, IgA and IgG4, IgG4/IgG ratio, as well as erythrocyte sedimentation rate (ESR) in
IgG4-RD patients (n = 28) were analyzed by Pearson’s rank test (A-F). Correlations between the percentages of CD19 + CD24-CD38hi B cells and levels
of IgG, IgM, IgA and IgG4, IgG4/IgG ratio, as well as ESR in IgG4-RD patients were analyzed by Pearson’s rank test (G-L).
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Breg cells were deficient in inhibiting proinflammatory
cytokine production by Teff. The Breg function from
IgG4-RD patients was not detected because of limited cell
numbers. Similarly, Knippenberg and colleagues reported
that the percentages of both memory B cells and Bregsfrom patients with stable and active multiple sclerosis
were markedly decreased compared to HC [22].
CD40 signaling is critical for Breg cell generation and
function in autoimmune disorders [23]. However, Blair
et al. demonstrated that isolated CD19 + CD24hiCD38hi
B cells from systemic lupus erythematous (SLE) patients
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less IL-10, and were deficient in suppressive capacity com-
pared with their healthy counterparts [11]. In our study,
CD40L-stimulated peripheral B cells from IgG4-RD pa-
tients did not induce an increase in Breg cells. One pos-
sible explanation is that for an unknown reason, Breg cells
in IgG4-RD patients are not only deficient in number but
also different in their response to CD40L stimulation.
Interestingly, we found a remarkable increase in the
expression of a particular B-cell subset, which was cha-
racterized with CD19 + CD24-CD38hi surface markers in
peripheral B cells from IgG4-RD patients; this B-cell
subset was expressed at fairly low levels in pSS and HC.
In addition, CD19 + CD24-CD38hi B cells positively cor-
related with serum IgG4 levels in IgG4-RD patients.
According to a previous study, the CD19 + CD24-CD38hi
B cell subset comprised pre-germinal center (pre-GC)
cells in tonsils, whereas there was no report of this
B-cell subset in peripheral blood [19]. In IgG4-RD pa-
tients, the characteristic changes in involved tissues are
massive infiltration of lymphocytes and IgG4+ plasma cells
with GC formation in the majority of patients [24,25].
Therefore, we assumed that in IgG4-RD patients, the
CD19 + CD24-CD38hi B cells may differentiate into IgG4
producing plasma cells or recruit to the involved tissues.
Further studies on this cell subset are needed.
It is well-established that BAFF, through BAFF-R, plays
a key role in B-cell activation and survival [26,27]. It is re-
ported that, over-expression of BAFF, participates in B cell
abnormalities in pSS, such as aberrant B-cell distribution,
B-cell hyperactivity, and autoantibody production [28,29].
As IgG4-RD patients are characterized with hypergamma-
globulinemia and high serum IgG4 levels, we hypothesize
that B cells from IgG4-RD patients might be in an en-
dogenously activated state, with highly expressed BAFF-R,
and readily differentiate into IgG/IgG4-secreting plasma
cells. Although IgG4-RD shares many features with pSS,
this study revealed that BAFF-R expression was sig-
nificantly decreased in peripheral B cells in patients with
IgG4-RD as compared with pSS and HC, whereas, the
serum levels of BAFF in patients with IgG4-RD were sig-
nificantly higher than those in HC. By stimulation with
rhBAFF, the MFI of BAFF-R was decreased in B cells from
healthy volunteers, consistent with the results of Sellam
et al., in which the decreased BAFF-R level was positively
correlated with serum BAFF levels and associated with
disease activity in pSS and SLE patients. Through post-
transcriptional regulation, such chronic elevated overpro-
duction of BAFF could downregulate BAFF-R expression
on the B-cell surface, and BAFF-R level could be a novel
activity biomarker in autoimmune diseases [30]. This may
explain our findings that the same post-transcriptional
regulation mechanism probably also occurred in IgG4-RD
and reflects chronic BAFF overproduction.Co-stimulatory factors play critical roles in T-cell and
B-cell activation, wherein the CD40-CD40L and CD28-
CD80/CD86 pathways are well known to cross-talk be-
tween T and B cells. CD40, a TNF superfamily trans-
membrane glycoprotein, plays an important role in B-cell
differentiation and activation [31]. When activated with its
ligand, CD40 provides a co-stimulatory signal which in-
duces T cell-dependent B-cell proliferation and differen-
tiation with subsequent immunoglobulin production. Ping
et al. found that CD40 signals promote Fas-dependent
death of pSS salivary epithelial cells by downregulating
cellular FLICE-like inhibitory protein (c-FLIP) expression
[32]. Our previous work has proved that CD40-induced
nuclear factor (NF)-kB activation is different in human
lupus B lymphocytes compared with normal B cells [33].
In addition, CD40 signaling is important for Breg cell pro-
duction, as Breg cells can be induced by CD40 stimulation
[34]. We evaluated CD40 expression in IgG4-RD, pSS and
HC; the results not only revealed that in IgG4-RD patients
CD19+ B lymphocytes expressed a lower frequency of
CD40, but that decreased MFI of CD40 was also found in
all B-cell subsets including regulatory, memory, and ma-
ture B cells from IgG4-RD patients. Furthermore, CD40
stimulation could not induce Breg cell expression. There-
fore, our findings suggest that in IgG4-RD patients,
CD40/CD40L signaling was aberrant in inducing Breg cell
differentiation.
In contrast to CD40 expression, we found that both
CD80 and CD86 expression on CD19+ B cells were sig-
nificantly increased in patients with IgG4-RD, whereas
their expression on CD19+ B cells was comparable bet-
ween pSS and HC groups. Aberrant CD86 expression on
B lymphocytes has been reported in many autoimmune
diseases and T helper (Th)2 cells are polarized by CD86
[35]. Bijl et al. also showed the expression of CD86 on
CD19+ B cells was increased and associated with B-cell
activation [36]. In addition, Jeannin et al. proved that to-
gether with IL-4 or IL-13 and CD40L, CD86 was condu-
cive to CD23-CD21 pairing, as the potential stimulating
factor for human IgE and IgG4 synthesis [37]. It is encour-
aging that our data suggest that elevated CD86 and CD80
on B cells from IgG4-RD patients promote IgG4 and IgE
synthesis. Moreover, previous studies have shown that the
polarization of Th2 cells in IgG4-RD patients [6]. Consis-
tent with these studies, our data showed Th2 polarization
in IgG4-RD patients and Th2 cytokines, IL-4, but not IL-5
or IL-13, was significantly increased in IgG4-RD patients.
Conclusions
Our data revealed that B-cell subsets were aberrant in
both IgG4-RD and pSS patiens. However, B cells displayed
differently in patients with IgG4-RD and pSS, including
disturbed B-cell subpopulations and key signaling mole-
cules, such as CD40, CD86, CD80 and BAFF-R. IgG4-RD
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B cells but increased memory B cells compared with pSS
patients and HC. Memory and CD19 + CD24-CD38hi
B cells were associated with IgG4 secretion. The function
of the CD19 + CD24-CD38hi B cell subsets in IgG4-RD re-
mains to be elucidated. Whether aberrant expression of
co-stimulatory molecules in patients with IgG4-RD corre-
lates with class-switch needs further investigation.
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